These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33297578)

  • 21. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
    J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
    Idée JM; Fretellier N; Robic C; Corot C
    Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relaxivity enhancement of aquated Tris(β-diketonate)gadolinium(III) chelates by confinement within ultrashort single-walled carbon nanotubes.
    Law JJ; Guven A; Wilson LJ
    Contrast Media Mol Imaging; 2014; 9(6):409-12. PubMed ID: 24764189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bifunctional Gd(III) and Tb(III) chelates based on a pyridine-bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging.
    Laurent S; Vander Elst L; Galaup C; Leygue N; Boutry S; Picard C; Muller RN
    Contrast Media Mol Imaging; 2014; 9(4):300-12. PubMed ID: 24706614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reaction of gadolinium chelates with ozone and hydroxyl radicals.
    Cyris M; Knolle W; Richard J; Dopp E; von Sonntag C; Schmidt TC
    Environ Sci Technol; 2013 Sep; 47(17):9942-9. PubMed ID: 23888885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gadolinium deposition-"gadolinium deposition disease"].
    Raczeck P; Fries P; Bücker A; Schneider G
    Radiologe; 2019 May; 59(5):435-443. PubMed ID: 30963195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer.
    Khantasup K; Saiviroonporn P; Jarussophon S; Chantima W; Dharakul T
    MAGMA; 2018 Oct; 31(5):633-644. PubMed ID: 29737435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes.
    Erdogan S; Roby A; Sawant R; Hurley J; Torchilin VP
    J Liposome Res; 2006; 16(1):45-55. PubMed ID: 16556549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents.
    Bornhorst J; Wegwerth P; Day P; Bryant S; Rokke D; Tervola R; Eckdahl S; Jannetto PJ
    Clin Chem Lab Med; 2020 Feb; 58(3):e87-e90. PubMed ID: 31622241
    [No Abstract]   [Full Text] [Related]  

  • 39. MRI micelles self-assembled from synthetic gadolinium-based nano building blocks.
    Babič A; Vorobiev V; Trefalt G; Crowe LA; Helm L; Vallée JP; Allémann E
    Chem Commun (Camb); 2019 Jan; 55(7):945-948. PubMed ID: 30604781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reductive microenvironment responsive gadolinium-based polymers as potential safe MRI contrast agents.
    Guo S; Xiao X; Wang X; Luo Q; Zhu H; Zhang H; Li H; Gong Q; Luo K
    Biomater Sci; 2019 Apr; 7(5):1919-1932. PubMed ID: 30773580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.